English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT02742090 /

TGR-1202-201

A Phase 2 Study To Assess The Safety And Efficacy Of TGR-1202 In Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant To Prior BTK (Bruton Tyrosine Kinase) Or PI3K-Delta (Phosphoinositide-3-Kinase) Inhibitor Therapy

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: